Ed Sheeran Compared to Other Public GLP-1 Figures

Why Comparing Celebrity GLP-1 Stories Matters

Between 2022 and 2025, a pattern repeated itself across tabloids and social media. A famous person lost visible weight. Within days, commentators speculated about semaglutide or tirzepatide. Sometimes the celebrity confirmed it. Sometimes they denied it. Sometimes they said nothing at all.

Ed Sheeran falls into that third category. His weight loss became noticeable during his 2023 tour cycle, and online speculation linked it to GLP-1 medications. Sheeran himself has credited changes in diet and exercise, not medication. No credible public source has documented him using semaglutide, tirzepatide, or any related drug.

That distinction matters. Conflating speculation with confirmed use undermines the experiences of celebrities who chose to disclose, and it misrepresents what these medications actually do.

The Confirmed GLP-1 Disclosure Timeline

Several public figures have confirmed GLP-1 receptor agonist use on the record. Their timelines and disclosure patterns differ substantially.

Oprah Winfrey confirmed in December 2023 that she had been using a GLP-1 medication as part of her weight management. She discussed it on a special episode of her program, framing it as a tool alongside behavioral changes. Winfrey later stepped down from the WeightWatchers board, citing a desire to discuss these medications without a conflict of interest.

Kelly Clarkson was the subject of intense public speculation throughout 2023. She initially attributed her weight loss to dietary changes and an active lifestyle in a June 2023 interview. In January 2024, she confirmed that a physician had prescribed her a weight-loss medication, though she did not name the specific drug.

Tracy Morgan publicly discussed his use of Ozempic (semaglutide) in 2023, describing the medication's effects on his appetite and energy levels in interviews.

Charles Barkley confirmed in 2024 that he had been using Mounjaro (tirzepatide), reporting significant weight loss and describing the experience in media appearances.

Each of these disclosures followed a period of public speculation. The gap between visible change and public confirmation ranged from weeks to over a year.

Where Ed Sheeran Fits

Ed Sheeran's situation is fundamentally different from the confirmed cases above. He has attributed his physical changes to lifestyle factors. No interviewer has reported him confirming GLP-1 use, and no medical professional has publicly linked him to these medications.

The speculation around Sheeran follows a recognizable pattern: rapid visible change in a male celebrity during a period when GLP-1 prescriptions surged globally. Between 2020 and 2024, prescriptions for semaglutide and tirzepatide grew by over 3,000% in the United States. That growth made GLP-1 medications the default assumption whenever a public figure appeared leaner.

The HealthRX.com Medical Team notes that this assumption ignores basic physiology. Weight loss of 10 to 20 pounds over several months is well within the range achievable through caloric restriction and increased physical activity alone, particularly for a touring musician whose schedule shifted from sedentary lockdown periods to months of nightly performances.

Clinical Context: What GLP-1 Drugs Actually Produce

GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce hunger. The STEP 1 trial demonstrated that semaglutide 2.4 mg weekly produced a mean weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even larger effects. The SURMOUNT-1 trial reported mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks.

These are population averages. Individual responses vary widely. Some patients lose 5% of body weight; others exceed 25%. The side effect profile is consistent across both drugs: nausea (reported in 40-44% of semaglutide patients in STEP 1), diarrhea, vomiting, and constipation are the most common adverse events. Most gastrointestinal symptoms are mild to moderate and decrease over time with dose escalation.

Less common but clinically significant risks include pancreatitis, gallbladder events, and potential thyroid C-cell concerns observed in rodent studies (a boxed warning on both drugs, though human epidemiological data has not confirmed increased medullary thyroid carcinoma risk).

The Disclosure Gap: What Clinicians Should Understand

The confirmed celebrity cases share a feature that matters for clinical practice. Every person who disclosed GLP-1 use described a period of reluctance before going public. Winfrey explicitly discussed the shame she felt. Clarkson initially deflected. The social pressure around weight-loss medication use remains significant, even for people whose careers do not depend on physical appearance.

The HealthRX.com Medical Team sees this reflected in prescribing data. A 2023 survey published in Obesity found that 42% of patients using anti-obesity medications had not told close family members. Celebrity disclosures, when they happen, can reduce that stigma. But forced speculation (applying a GLP-1 label to anyone who loses weight) risks reinforcing it.

For patients who are considering GLP-1 therapy, the clinical conversation should address several points that celebrity stories often skip:

• Maintenance requirements. The STEP 4 trial extension showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. These drugs require ongoing use for sustained effect.
• Contraindications. Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and known hypersensitivity to the drug or its components are absolute contraindications per FDA labeling.
• Cost and access. Monthly costs for brand-name semaglutide and tirzepatide range from $900 to $1,300 without insurance. Coverage varies significantly by plan, and prior authorization requirements are common.
• Muscle mass. GLP-1-mediated weight loss includes lean mass loss. The STEP 1 trial showed approximately 40% of weight lost was lean tissue. Resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) are recommended to attenuate this effect.

The Pattern Worth Watching

The split between Ed Sheeran's case and the confirmed disclosures illustrates something broader about how pharmaceutical information spreads through culture. Confirmed users become de facto spokespeople for a drug class. Speculated users become cautionary tales about public assumptions.

Neither role is chosen by the individual. Winfrey leaned into hers. Sheeran has not engaged with speculation at all, which is his prerogative.

The HealthRX.com Medical Team's position: public interest in celebrity medication use is understandable given the scale of GLP-1 adoption. But responsible discussion requires separating what is known from what is assumed. Ed Sheeran has not confirmed GLP-1 use. The clinical evidence shows that his reported methods (diet, exercise, lifestyle change) are capable of producing the results he has described. Both things can be true simultaneously: GLP-1 medications are effective, well-studied drugs, and not every instance of weight loss involves them.

At a glance

• Ed Sheeran has not publicly confirmed GLP-1 medication use
• He has attributed weight loss to diet and exercise changes
• Several other celebrities (Oprah Winfrey, Kelly Clarkson, Tracy Morgan, Charles Barkley) have confirmed GLP-1 use on the record
• Semaglutide produces average weight loss of ~15% over 68 weeks in clinical trials
• Tirzepatide produces average weight loss of 15-21% over 72 weeks depending on dose
• GLP-1 speculation about public figures accelerated alongside a 3,000%+ increase in U.S. prescriptions between 2020 and 2024

Frequently asked questions

›

›

›

›

›

References

• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
• Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425. PubMed
• GLP-1 receptor agonist prescribing trends in the United States, 2020-2024. JAMA. 2024. JAMA Network
• Patient disclosure patterns for anti-obesity medication use. Obesity. 2023. PubMed
• Pancreatic safety of GLP-1 receptor agonists: systematic review. PubMed
• FDA drug labeling for semaglutide and tirzepatide. FDA
• AHA/ACC guidelines on lifestyle management. AHA Journals